Adverse drug reactions (ADRs) are a significant public health concern and a leading cause
of hospitalization; they are estimated to be the fourth leading cause of death and increasing …

Pharmacogenomics (PGx) is an important component of precision medicine that promises
tailored treatment approaches based on an individual's genetic information. Exploring the …

Background: Population genomic studies of individuals of Indigenous ancestry have been
extremely limited comprising< 0.5% of participants in international genetic databases and …

Introduction Genetic variants contribute to differential responses to non-insulin antidiabetic
drugs (NIADs), and consequently to variable plasma glucose control. Optimal control of …

Genetic ancestry plays a major role in pharmacogenomics, and a deeper understanding of
the genetic diversity among individuals holds immerse promise for reshaping personalized …

Background Monogenic dyslipidemia is a group of inherited genetic disorders characterized
by abnormal levels of lipids and lipoproteins in blood, contributing to a significant risk for …

Adverse drug reactions (ADRs) pose substantial public health issues, necessitating
population-specific characterization due to variations in pharmacogenes. This study …

The availability of a reference human genome, the advent of next-generation sequencing
technologies and the consequent rapidly plummeting costs of sequencing an individual's …

Proton-pump inhibitors (PPIs) are widely prescribed to decrease stomach acid and treat
various acid-related Gastrointestinal tract (GIT) diseases. However, genetic variations …

Pharmacogenetics (PGx) aims to identify the genetic factors that determine inter-individual
differences in response to drug treatment maximizing efficacy while decreasing the risk of …